A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma

Recruiting

Phase 1

ATP150/ATP152, VSV-GP154, EzabenlimabA Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma

Sponsor:

Amal Therapeutics

Code:

NCT05846516

Conditions

Pancreatic Ductal Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

VSV-GP154

ATP150

ATP152

Ezabenlimab

ATP162

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-18. This information was provided to ClinicalTrials.gov by Amal Therapeutics on 2025-09-18.